Which manufacturer develops and produces ritexitinib?

Ritlecitinib is produced by Pfizer of the United States and is used to treat severe alopecia areata. On June 23, 2023, ritexitinib was approved in the United States for the treatment of severe alopecia areata in adults and adolescents aged 12 years and older. Ritexitinib was approved in Japan on June 26, 2023 for the treatment of alopecia areata (limited to refractory cases involving extensive hair loss).

Ritexitinib increases the risk of serious bacterial, fungal, viral, and opportunistic infections that may lead to hospitalization or death, including tuberculosis (TB). If severe infection occurs, treatment should be interrupted until the infection is controlled. Ritexitinib should not be used in patients with active pulmonary tuberculosis. Detect latent tuberculosis before and during treatment and initiate treatment for latent tuberculosis before use. Monitor all patients for active tuberculosis during treatment, even those with initially negative latent tuberculosis. Monitor all patients for signs and symptoms of infection during and after treatment with ritixitinib. Patients with rheumatoid arthritis (RA) treated with another Januskinase inhibitor (JAK) were associated with higher all-cause mortality, including sudden cardiovascular death, compared with TNF blockers. Ritexitinibis not approved for RA patients. Malignancies have been reported in patients treated withritixitinib. In patients with rheumatoid arthritis, use of anotherJAKinhibitor was associated with a higher incidence of lymphoma and lung cancer compared with use of a tumor necrosis factor blocker. In patients with rheumatoid arthritis, another JAK inhibitor was associated with a higher incidence of MACE (defined as cardiovascular death, myocardial infarction, and stroke) compared with tumor necrosis factor blockers. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0